Search results for "CoVID-19 vaccine"

showing 10 items of 61 documents

COVID-19 infection in cancer patients: what has been the contribution of Associazione Italiana Oncologia Medica (AIOM) to oncological care since the …

2021

High mortality rates in elderly patients or in those with underlying chronic illnesses and/or a compromised immune system is a peculiar feature of COVID-19 infection. The possible coexistence of a cancer and COVID-19 infection in the same individual prompted concerns regarding their synergistic effect on prognosis. In order to balance patients’ needs with the risks related to the infection, the question oncologists have asked from the beginning of the first wave of the pandemic has been: ‘how can we deal with COVID-19 infection in cancer patients?’ In pursuing its mission, the Associazione Italiana Oncologia Medica (AIOM) has made every possible effort to support cancer patients, health car…

Cancer Research2019-20 coronavirus outbreakmedicine.medical_specialtyCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)FAVO Federazione delle Associazioni di Volontariato in OncologiaReviewWHO World Health OrganizationCIPOMO Italian College of Primary Hospital Medical OncologistsSICO Società Italiana di Chirurgia OncologicaMedicalNeoplasmsHealth carePandemicMedicinecancerCentral Venous CathetersHumansFNOPI Federazione Nazionale Ordini Professioni InfermieristicheSocieties MedicalAIRO Associazione Italiana Radioterapia e Oncologia clinicaOncologistsClinical Trials as Topictreatmentbusiness.industryHigh mortalityAIOM Associazione Italiana di Oncologia medicaCancerNeoplasms therapyAIOM; cancer; COVID-19; treatment; vaccination; Central Venous Catheters; Clinical Trials as Topic; Humans; Influenza Vaccines; Oncologists; Practice Guidelines as Topic; COVID-19; COVID-19 Vaccines; Neoplasms; Societies MedicalCOVID-19medicine.diseasevaccinationCOMU College of University Medical OncologistsOncologyInfluenza VaccinesFamily medicineFOCE ConFederazione degli Oncologi Cardiologi e EmatologiPractice Guidelines as TopicESMO European Society for Medical OncologybusinessSocietiesSIPO Società Italiana di Psico-OncologiaAIOMESMO open
researchProduct

Spanish Society of Hematology and Hemotherapy expert consensus opinion for SARS-CoV-2 vaccination in onco-hematological patients.

2021

Abstract In the midst of the COVID-19 pandemic, different vaccines in front of SARS-CoV-2 have been approved and administered in different vulnerable populations. As patients with cancer were excluded from pivotal trials of vaccination, little is known on their immunogenic response to these vaccines, particularly in patients with severely impaired immune system. In response to that uncertainty, the Spanish Society of Hematology and Hemotherapy launched an initiative aimed to provide recommendations for vaccination of the main hematological conditions. This document is based on the available information on COVID-19 outcomes, prior knowledge on vaccination in hematological patients, recent pu…

Cancer Researchmedicine.medical_specialtyCOVID-19 VaccinesConsensusCoronavirus disease 2019 (COVID-19)myeloproliferative neoplasmSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)lymphomaReviewstem cell transplantationCOVID-19 SARS-CoV-2 vaccine acute leukemia allogeneic stem cell transplantation lymphoma myelodisplastic syndrome myeloproliferative neoplasm onco-hematology stem cell transplantation vaccination consensusallogeneic stem cell transplantationSARS-CoV-2 vaccineInternal medicinePandemicmedicineHemotherapyHumansIn patientacute leukemiaIntensive care medicineExpert TestimonyPandemicsonco-hematologyHematologySARS-CoV-2business.industryVaccinationCOVID-19Expert consensusHematologyVaccinationvaccination consensusOncologymyelodisplastic syndromebusiness
researchProduct

COVID 19 vaccine in the pediatric age: the recommendation of the Italian Pediatric Society

2022

AbstractVaccine is an important and effective tool to protect from preventable infectious diseases. Neverthless, in the COVID-19 pandemic era, scientific and accurate information are required to responde to false and misleading information on efficacy and safety of immunization in the pediatric age.

Covid-19 vaccineVaccinesCOVID-19 VaccinesPandemicVaccinationHesitancyCOVID-19HumansChildren Covid-19 vaccine HesitancyChildChildrenPandemicsHumanItalian Journal of Pediatrics
researchProduct

Determinants of COVID-19 Vaccine Rollouts and Their Effects on Health Outcomes

2022

Background Vaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases, fatalities, intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results…

Economics and Econometricsand (iii) COVID-19 cases in neighboring countries can lead to an increase in a country's domestic caseload and hamper efforts in taming its own local outbreak. Conclusions: By providing an early broad overview of the quantitative empirical estimates of the determinants of vaccine rollouts and the effects of COVID-19 vaccines our paper can help policymakers make informed decisions about local and global distributions of vaccines as well as related policy tools such as containment measure.Coronavirus disease 2019 (COVID-19)business.industryHealth PolicyNational accountsOutbreakGeneral Medicine(ii) vaccine deployment significantly reduces new COVID-19 infections Intensive Care Unit (ICU) admissions and fatalities and is more effective when coupled with stringent containment measures or when a country is experiencing a large outbreakVaccination against the coronavirus disease (SARS-CoV-2) is understood to be the key way out of the COVID-19 pandemic. Limited evidence exists on the determinants of vaccine rollouts and their health effects at the country level. Objective: Examine the determinants of COVID-19 vaccine rollouts and their effects on health outcomes. Methods: Ordinary least squares regressions with standard errors clustered at the country level for Cross-section and Panel daily data of vaccinations and various health outcomes (new COVID-19 cases fatalities intensive care unit (ICU) admissions) for an unbalanced sample of about 200 countries during the period 16 December 2020 to 20 June 2021. Results: We find evidence that: (i) early vaccine procurement domestic production of vaccines the severity of the pandemic a country's health infrastructure and vaccine acceptance are significant determinants of the speed of vaccination rolloutHealth outcomesIntensive care unitlaw.inventionVaccinationProcurementlawEnvironmental healthPandemicGeneral Earth and Planetary SciencesMedicinebusinessGeneral Environmental ScienceIMF Working Papers
researchProduct

Adherence and Reactogenicity to Vaccines against SARS-COV-2 in 285 Patients with Neuropathy: A Multicentric Study

2022

Background: The safety of the new vaccines against SARS-CoV-2 have already been shown, although data on patients with polyneuropathy are still lacking. The aim of this study is to evaluate the adherence to SARS-CoV-2 vaccination, as well as the reactogenicity to those vaccines in patients affected by neuropathy. Methods: A multicentric and web-based cross-sectional survey was conducted among patients affected by neuropathy from part of South Italy. Results: Out of 285 responders, n = 268 were included in the final analysis and n = 258 of them (96.3%) were fully vaccinated. Adherence to vaccination was higher in patients with hereditary neuropathies compared to others, while it was lower in …

General NeuroscienceSARS-CoV-2 infectionCIDP COVID-19 vaccines SARS-CoV-2 infection autoimmune neuropathy hereditary neuropathy neuropathy reactogenicity vaccine hesitancy vaccine safetyreactogenicityvaccine hesitancySARS-CoV-2 infection; COVID-19 vaccines; reactogenicity; vaccine safety; vaccine hesitancy; neuropathy; autoimmune neuropathy; hereditary neuropathy; CIDPneuropathyvaccine safetyCIDPhereditary neuropathyCOVID-19 vaccineautoimmune neuropathy
researchProduct

Clinical update on risks and efficacy of anti-SARS-CoV-2 vaccines in patients with autoimmune hepatitis and summary of reports on post-vaccination li…

2022

Patients with liver diseases, especially those with cirrhosis, have an increased mortality risk when infected by SARS-CoV-2 and therefore anti-SARS-CoV-2 vaccine has been recommended by leading Scientific Associations for all patients with chronic liver diseases. However, previous reports have shown a reduced antibody response following the full course of vaccination in immunosuppressed patients, including liver transplant recipients and several rheumatic diseases. This document, drafted by an expert panel of hepatologists appointed by the Italian Association for the Study of the Liver (AISF), aims to present the updated scientific data on the safety and efficacy of anti-SARS-CoV-2 mRNA vac…

Hepatitis AutoimmuneSettore MED/12 - GastroenterologiaCOVID-19 VaccinesHepatologySARS-CoV-2Liver DiseasesVaccinationGastroenterologyCOVID-19HumansSARS-CoV-2 mRNA vaccines autoimmune hepatitis immunosoppressionDigestive and Liver Disease
researchProduct

Global health security and islands as seen through COVID-19 and vaccination

2022

Since the declaration of COVID-19 as a pandemic in March 2020, significant research and attention has focused on countries’ abilities and interests in enacting response measures to the spread of the coronavirus including lockdowns, travel restrictions, and vaccination programmes to contain infections, hospitalisations, and deaths. As the pandemic has continued, much discussion has also centred on the ability of islands to control borders, enact public health measures, and keep the virus out or controlled, owing in part to presumed islandness characteristics of isolation and remoteness. Drawing from ongoing empirical examples of island experiences in the context of COVID-19, this article exa…

IslandsCOVID-19 VaccinesVDP::Medisinske Fag: 700::Helsefag: 800::Samfunnsmedisin sosialmedisin: 801SARS-CoV-2RA0421 Public health. Hygiene. Preventive MedicineCommunicable Disease ControlVaccinationPublic Health Environmental and Occupational HealthCOVID-19HumansGlobal HealthHV Social pathology. Social and public welfare. Criminology
researchProduct

SARS-CoV-2 infection in patients with a normal or abnormal liver.

2020

Abstract Severe acute respiratory syndrome coronavirus‐2 (SARS‐CoV‐2), a novel coronavirus causing coronavirus disease 19 (COVID‐19), with an estimated 22 million people infected worldwide so far although involving primarily the respiratory tract, has a remarkable tropism for the liver and the biliary tract. Patients with SARS‐CoV‐2 infection and no antecedent liver disease may display evidence of cytolytic liver damage, proportional to the severity of COVID‐19 but rarely of clinical significance. The mechanism of hepatocellular injury is unclear and possibly multifactorial. The clinical impact of SARS‐CoV‐2 infection in patients with underlying chronic liver disease, a cohort whose global …

Liver CirrhosisRiskmedicine.medical_specialtyCirrhosisCOVID-19 VaccinesCOVID-19 VaccineLiver CirrhosiPopulationDiseaseChronic liver diseasemedicine.disease_causeSARS‐CoV‐2Liver diseaseCOVID‐19VirologyInternal medicinevaccinemedicineHumansClinical significanceeducationCoronaviruseducation.field_of_studySettore MED/12 - GastroenterologiaHepatologybusiness.industryTransmission (medicine)SARS-CoV-2Liver DiseasescirrhosisCOVID-19chronic liver diseaseprioritizationmedicine.diseaseInfectious DiseasesLiverNon‐commissioned ReviewChronic DiseasebusinesscirrhosiHumanJournal of viral hepatitis
researchProduct

Prevalence of unwillingness and uncertainty to vaccinate against COVID-19 in older people: A systematic review and meta-analysis.

2021

The coronavirus disease 2019 (COVID-19) has been shown to have more severe health outcomes in older people specifically in relation to mortality and disability. Vaccination seems to be efficacious and safe for preventing the negative consequences of COVID-19, but vaccine hesitancy seems to be high in older adults. We therefore aimed to investigate the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in older people and the factors that can be associated with the unwillingness to vaccinate. For this work, we searched several databases until 18th June 2021 for studies reporting the prevalence of unwillingness and the uncertainty to vaccinate against COVID-19 in pe…

Low incomeAgingCOVID-19 VaccinesCoronavirus disease 2019 (COVID-19)ReviewHealth outcomesBiochemistryolder adultvaccinePrevalenceMedicineHumansMolecular Biologyolder adultsAgedbusiness.industrySARS-CoV-2VaccinationUncertaintyCOVID-19Odds ratioConfidence intervalVaccinationCross-Sectional StudiesNeurologyMeta-analysisCOVID-19; hesitancy; older adults; vaccine; Aged; Cross-Sectional Studies; Humans; Prevalence; SARS-CoV-2; Uncertainty; Vaccination; COVID-19; COVID-19 VaccineshesitancyOlder peoplebusinessBiotechnologyDemographyAgeing research reviews
researchProduct

Immunogenicity of the BNT162b2 mRNA COVID-19 vaccine in older residents of a long-term care facility: relation with age, frailty and prior infection …

2021

Clinical and biological assessment of the COVID-19 vaccine efficacy in the frail population is of crucial importance. The study focuses on measuring the levels of anti-SARS-CoV-2 IgG antibodies before and after BNT162b2 mRNA COVID-19 vaccination among long-term care facility (LTCF) elderly residents. We conducted a prospective, single-center, observational study among LTCF residents. The study protocol was based on three blood sample acquisitions: first taken at baseline—5 days before the first dose of the vaccine, second—20 days after the first dose, and third—12 days after the second shot of the vaccine. The comparison was made for two cohorts: patients with and without prior COVID-19 inf…

MaleAgingFrailtySARS-CoV-2COVID-19COVID-19 vaccinesLong-term careImmunogenicity VaccineOlder adultsHumansFemaleProspective StudiesRNA MessengerGeriatrics and GerontologyGerontologyBNT162 VaccineResearch ArticleAgedBiogerontology
researchProduct